文献速递产科母胎医学

剖宫产预防性氨甲环酸在高血压与非高血压患者中的效果

Tranexamic Acid Prophylaxis During Cesarean Delivery Among Patients with and Without Hypertension.
PubMed 文献 · Am J Obstet Gynecol MFM · 2026-11-04

本研究为多中心安慰剂对照试验的事后二次分析,纳入10995例剖宫产患者,其中24.6%有高血压。比较预防性氨甲环酸1g与安慰剂对围产期出血结局的影响,发现效果不因高血压状态而异。

要点

  • 高血压患者剖宫产预防性氨甲环酸对输血或死亡复合结局无显著差异。
  • 高血压与非高血压患者交互作用P=0.64,所有次要结局交互作用P>0.05。
  • 高血压患者中氨甲环酸组复合结局4.9% vs 安慰剂6.0%,RR 0.84(95%CI 0.62-1.16)。

核心结论

  • 剖宫产预防性氨甲环酸对输血或产后一周内死亡等出血相关结局的效果不因高血压状态而异。

研究设计与样本

  • 多中心安慰剂对照试验的非预设二次分析,纳入10995例剖宫产患者,随机接受氨甲环酸1g或安慰剂。

主要发现

  • 高血压患者中氨甲环酸组主要复合结局4.9% vs 安慰剂6.0%,RR 0.84(95%CI 0.62-1.16)。
  • 非高血压患者中氨甲环酸组主要复合结局3.2% vs 安慰剂3.7%,RR 0.91(95%CI 0.73-1.14)。
  • 高血压状态与治疗交互作用P=0.64,所有次要结局交互作用P>0.05。

临床怎么用

  • 剖宫产时预防性使用氨甲环酸无需因高血压状态而调整预期效果。

局限性

  • 本研究为非预设二次分析,高血压亚组样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with chronic and pregnancy-related hypertension are at increased risk of postpartum hemorrhage and have fewer uterotonic options because methylergonovine is generally contraindicated. Hypertensive disorders are also characterized by endothelial dysfunction and altered coagulation-fibrinolytic pathways, providing biologic plausibility that tranexamic acid (TXA) may have differential effects in this population. OBJECTIVE: The objective of this study was to examine whether the effect of prophylactic TXA during cesarean delivery (CD) on peripartum bleeding-related outcomes differed based on hypertensive status. STUDY DESIGN: This is a non-prespecified secondary analysis of a multicenter, placebo-controlled trial of patients undergoing CD who were randomized to 1gram of TXA or placebo. For this analysis, all participants were included and divided into subgroups based on the presence of chronic and pregnancy-related hypertension (HTN) prior to delivery. The primary outcome was a composite of blood transfusion or maternal death before hospital discharge or seven days postpartum, whichever occurred first. Secondary outcomes included several measures of peri-partum bleeding related outcomes. Relative risks (RR) and 95% confidence intervals (CI) were calculated for categorical and mean differences for continuous outcomes. P values for interaction with HTN were calculated. RESULTS: Of the 10,995 participants randomized in the parent trial, 2707 (24.6%) had HTN (7.1% chronic hypertension and 17.5% pregnancy related). The effect of TXA on the primary outcome did not differ by HTN status at randomization (HTN: TXA 4.9% vs placebo 6.0%; RR 0.84 (95% CI 0.62-1.16); no HTN: TXA 3.2% vs placebo 3.7%; RR 0.91 (0.73-1.14); p for interaction 0.64). For all secondary outcomes, the interaction p similarly was non-significant (all p >0.05). CONCLUSION: The effect of prophylactic TXA at CD on blood transfusion or maternal death within one week postpartum, or other peripartum bleeding-related outcomes, did not differ by the presence of HTN.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Ayyash MK, Lewkowitz AK, Weiner SJ, et al. Tranexamic Acid Prophylaxis During Cesarean Delivery Among Patients with and Without Hypertension. Am J Obstet Gynecol MFM. 2026. PMID: 42982133. doi:10.1016/j.ajogmf.2026.102184

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。